Namida develops and markets patented at-home cancer screening tests for early detection utilizing protein biomarkers found in tears. Namida's first early detection cancer screening test is for breast cancer and is called Auria (https://www.auria.care), which helps fill the significant gaps in image-based screening.
There are significant gaps in the current breast cancer standard of care, mammography. Additionally, late cancer detection significantly increases treatment costs.
- Half of women do not get annual mammograms.
- Women under 40 are not eligible for a covered mammogram.
- Half of women have dense breast tissue, for whom mammograms are not effective.
Namida has sold over 4,000 cancer screening tests across B2B and B2C markets, totaling over $500,000 in revenue.
